ACTRN12612000845831进行中（未招募）未知
For patients affected by relapsing Idiopathic Retroperitoneal Fibrosis, will treatment with Methotrexate plus Prednisone be effective in achieving and mantaining disease remission.
Augusto Vaglio0 个研究点目标入组 15 人开始时间: 2012年8月13日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 85 Years（—）
- 性别
- All
入选标准
- •Diagnosis of relapsing idiopathic retroperitoneal fibrosis and an age between 18 and 85 years.
排除标准
- •Pregnancy, active infections or malignancies, known hypersensitivity to the study drugs, uncontrolled diabetes and retroperitoneal fibrosis secondary to known causes.
研究者
相似试验
招募中
2 期
Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-BBzeta retroviral vector – A unicenter Phase I/II clinical trial [HD-CAR-1]2024-516832-82-00Universitaetsklinikum Heidelberg AöR63
已完成
2 期
Velcade™ (bortezomib) combination chemotherapy in AL amyloidosisCancerISRCTN33283585niversity College London (UCL) (UK)52
已完成
不适用
Intermittent rehabilitation in the therapy of type two diabetesType two diabetesNutritional, Metabolic, EndocrineISRCTN23033749Refonet (Germany)420
已完成
4 期
Prehabilitation intervention for patients undergoing elective colectomy: a prospective observational study utilizing a leucine-enriched beveragesarcopeniaJPRN-jRCT1091220321Otsuka Pharmaceutical Factory,Inc.80
进行中（未招募）
1 期
A clinical study to provide the opportunity to be treated with CTL019, an investigational gene therapy, for children and adolescent patients with a recurrent form of B-cell acute lymphoblastic leukaemia after the closure of the Novartis single-arm phase II pivotal registration trial (Study CCTL019B2202) and to collect additional safety information.Paediatric/young adult patients with B-cell acute lymphoblastic leukaemia who are chemo-refractory, relapsed after allogeneic SCT, or are otherwise ineligible for allogeneic SCT.MedDRA version: 19.1 Level: LLT Classification code 10063625 Term: Acute lymphoblastic leukemia recurrent System Organ Class: 100000004864MedDRA version: 19.1 Level: LLT Classification code 10063621 Term: Acute lymphoblastic leukaemia recurrent System Organ Class: 100000004864EUCTR2016-001991-31-ESovartis Farmacéutica, S.A.55